![]() |
市场调查报告书
商品编码
1692400
胃滞留药物输送系统外包市场 - 全球产业规模、份额、趋势、机会和预测,按剂型(片剂、液体、微球、胶囊等)区域和竞争细分,2020-2030 年Gastroretentive Drug Delivery Systems Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others) Region and Competition, 2020-2030F |
2024 年全球胃滞留药物输送系统外包市场价值为 13.7 亿美元,预计到 2030 年将达到 18.9 亿美元,预测期内复合年增长率为 5.51%。全球胃滞留药物输送系统外包市场是製药和医疗保健产业内一个充满活力且快速发展的产业。胃滞留给药系统是指使药物能够在胃中停留较长时间的专门配方和技术,从而实现控制释放和标靶治疗效果。由于对提高药物生物利用度、改善患者依从性并减少副作用的新型药物输送系统的需求不断增加,该细分市场正在经历显着增长。
市场概况 | |
---|---|
预测期 | 2026-2030 |
2024 年市场规模 | 13.7 亿美元 |
2030 年市场规模 | 18.9 亿美元 |
2025-2030 年复合年增长率 | 5.51% |
成长最快的领域 | 平板电脑 |
最大的市场 | 北美洲 |
胃肠道疾病等慢性疾病的发生率不断上升,需要有效且患者友善的药物传递解决方案。此外,人口老化和对先进製药技术认识的不断提高正在推动对胃滞留药物输送系统的需求。製药业越来越多地将这些系统的开发和製造外包给专门的合约研究组织(CRO)和合约製造组织(CMO),以利用他们的专业知识并缩短产品上市时间。
该市场的特点是外包服务种类繁多,包括配方开发、临床前和临床测试以及胃滞留药物输送系统的商业规模生产。 CRO 和 CMO 在提供涵盖研发、技术选择、法规遵循和品质保证的端到端解决方案方面发挥关键作用。因此,製药公司可以专注于药物发现和临床开发的核心竞争力,同时依靠外包合作伙伴来获得胃滞留药物输送的专业知识。
此外,区域扩张、策略合作以及研发活动的投资也促进了市场的快速成长。随着新型胃滞留药物传递技术的发展,市场正在经历创新的热潮,包括漂浮系统、生物黏合系统和可扩展系统。
胃肠道疾病盛行率上升
智慧财产权问题
靶向药物传输需求不断增长
Global Gastroretentive Drug Delivery Systems Outsourcing Market was valued at USD 1.37 billion in 2024 and is expected to reach USD 1.89 billion by 2030 with a CAGR of 5.51% during the forecast period. The Global Gastroretentive Drug Delivery Systems Outsourcing Market is a dynamic and rapidly evolving sector within the pharmaceutical and healthcare industry. Gastroretentive drug delivery systems refer to specialized formulations and technologies that enable drugs to be retained in the stomach for an extended period, facilitating controlled release and targeted therapeutic effects. This market segment is witnessing significant growth due to the increasing demand for novel drug delivery systems that enhance drug bioavailability, improve patient compliance, and reduce side effects.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 1.37 Billion |
Market Size 2030 | USD 1.89 Billion |
CAGR 2025-2030 | 5.51% |
Fastest Growing Segment | Tablets |
Largest Market | North America |
the rising prevalence of chronic diseases, such as gastrointestinal disorders, which require effective and patient-friendly drug delivery solutions. Moreover, an aging population and increasing awareness of advanced pharmaceutical technologies are propelling the demand for gastroretentive drug delivery systems. The pharmaceutical industry is increasingly outsourcing the development and manufacturing of these systems to specialized contract research organizations (CROs) and contract manufacturing organizations (CMOs) to leverage their expertise and reduce time-to-market.
The market is characterized by a diverse range of outsourcing services, including formulation development, preclinical and clinical testing, and commercial-scale production of gastroretentive drug delivery systems. CROs and CMOs are playing a pivotal role in offering end-to-end solutions that encompass research and development, technology selection, regulatory compliance, and quality assurance. As a result, pharmaceutical companies can focus on their core competencies in drug discovery and clinical development, while relying on outsourcing partners for specialized expertise in gastroretentive drug delivery.
Furthermore, regional expansion, strategic collaborations, and investments in research and development activities are contributing to the market's rapid growth. The market is witnessing a surge in innovation, with the development of novel gastroretentive drug delivery technologies, including floating systems, bio adhesive systems, and expandable systems.
Key Market Drivers
Rising Prevalence of Gastrointestinal Disorders
The rising prevalence of gastrointestinal disorders is a pivotal driver behind the growth of the Global Gastroretentive Drug Delivery Systems Outsourcing Market. Gastrointestinal conditions, such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease, and peptic ulcers, are becoming increasingly common worldwide. These disorders can significantly impact an individual's quality of life and managing them effectively often requires specialized pharmaceutical interventions.
According to World Gastroenterology Organisation, overall, 49% of females and 36.6% of males met criteria for at least one FGID - the most common disorders in all regions being functional constipation, functional dyspepsia, proctalgia fugax, functional diarrhea and IBS at prevalence rates of 11.7%, 7.2%, 5.9%, 4.7% and 4.1, respectively.
Gastroretentive drug delivery systems play a crucial role in addressing the challenges associated with treating gastrointestinal disorders. These innovative systems allow drugs to remain in the stomach for an extended period, ensuring localized treatment and controlled release of therapeutic agents. This approach not only enhances the bioavailability of drugs but also minimizes side effects and maximizes the effectiveness of treatment, providing much-needed relief to patients suffering from gastrointestinal ailments.
Key Market Challenges
Intellectual Property Concerns
In the competitive world of pharmaceuticals, companies invest heavily in research and development to create proprietary innovations, including gastroretentive drug delivery technologies. These innovations often form the core of their product portfolio and protecting them through IP rights is essential for maintaining a competitive edge. The fear of losing exclusive rights to these innovations can lead to hesitancy in sharing proprietary information with outsourcing partners, potentially hampering collaboration.
Collaborations between pharmaceutical companies and contract research organizations (CROs) or contract manufacturing organizations (CMOs) require a degree of information exchange. For the successful development and manufacturing of gastroretentive drug delivery systems, there's a need to share critical data, formulation knowledge, and technical expertise. However, striking the right balance between knowledge sharing and IP protection can be challenging. Pharmaceutical companies must carefully manage their IP while ensuring that their outsourcing partners have the necessary information to deliver high-quality products.
Key Market Trends
Increasing Demand for Targeted Drug Delivery
The Global Gastroretentive Drug Delivery Systems Outsourcing Market is experiencing a significant boost due to the increasing demand for targeted drug delivery solutions. This surge in demand is fueled by several factors and represents a key driving force shaping the future of the pharmaceutical outsourcing industry.
One of the most prominent factors driving the increasing demand for targeted drug delivery is the growing recognition of the limitations of traditional drug delivery methods. Conventional oral drug delivery often lacks specificity, with drugs being absorbed throughout the gastrointestinal tract. This can lead to reduced drug bioavailability and increased side effects, making it less than ideal for many therapeutic applications.
gastroretentive drug delivery systems offer a highly effective means of targeting specific regions within the gastrointestinal tract, particularly the stomach. These systems allow drugs to remain in the stomach for an extended duration, ensuring that they are delivered precisely where they are needed. This localized, site-specific approach not only enhances drug bioavailability but also minimizes unwanted side effects, improving the overall therapeutic outcomes for patients.
In this report, the Global Gastroretentive Drug Delivery Systems Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Gastroretentive Drug Delivery Systems Outsourcing Market.
Global Gastroretentive Drug Delivery Systems Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: